INHIBITION OF INTERLEUKIN 6 IN IMMUNE INFLAMMATORY RHEUMATIC DISEASES: ACHIEVEMENTS, PROSPECTS, AND HOPES
Much attention has been recently paid to the study of interleukin 6 (IL-6) among the cytokines involved in the development of immune inflammatory rheumatic diseases (IIRDs). The introduction of monoclonal antibodies that inhibit the activity of IL-6 (tocilizumab, TCZ) in clinical practice in 2010 is...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2018-01-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/2461 |